Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed-eluting vs doxorubicin-eluting beads in intermediate/late hepatocellular carcinoma
ChiCTR2000036312Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of raltitrexed in hepatocellular carcinoma (HCC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-free survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
raltitrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000036312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036312.